leucine rich repeat containing 37 member A13, pseudogeneGenealiases: []
Q-omics provides the consensus-scored LRRC37A13P profile across patient tissues and cancer cell-line models. LRRC37A13P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRRC37A13P is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, LRRC37A13P RNA expression shows 6,442 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where LRRC37A13P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37A13P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37A13P survival associations across molecular data types. LRRC37A13P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37A13P RNA expression–survival associations across cancer types. High LRRC37A13P expression shows unfavorable associations in KIRC, CHOL, THCA, READ and KICH, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRRC37A13P RNA expression.
This table summarizes LRRC37A13P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37A13P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37A13P shows higher tumor expression in KIRC, CHOL, COAD and KICH. The KIRC box plot shows higher LRRC37A13P RNA expression in tumor versus normal tissue (log2 FC = +0.071, t-test p = .024).
This table shows molecular features associated with LRRC37A13P in patient tissues and cancer cell lines. In patient samples, LRRC37A13P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
